Pafolacianine Drug Asset Due Diligence Report 2026

This Pafolacianine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Pafolacianine can convert its Small molecule drug, Fluorescent dyes profile and FOLR1 x FOLR2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Pafolacianine (query alias: Pafolacianine)
Modality / target	Small molecule drug, Fluorescent dyes; FOLR1 x FOLR2; FOLR1 agonists, FOLR2 agonists, PET imaging
Highest global status	Approved
Originator	On Target Laboratories, Inc.
Active developers	On Target Laboratories, Inc., University of California, Irvine, Abramson Cancer Center

The MCP disease footprint includes Lung Cancer, Contrast agents, Ovarian Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07469202	Phase 4	Not yet recruiting	106	Tumor-to-background ratio
NCT07124351	Phase 4	Recruiting	15	Feasibility of CYTALUX™ (pafolacianine) with near-infrared (NIR) fluorescent imaging
NCT07039526	Phase 2	Recruiting	50	Proportion of subjects with one or more NIR fluorescence positive lesion not detected under normal light and/or palpation

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 2, Single Dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

Phase 2; n=100; evaluation: not stated. Reported fields: Sensitivity or True Positive Rate (TPR) = 0.854 proportion of lesions (95% Confidence Interval, 0.74 - 0.92); -; -

A Phase 3, Randomized,Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

Phase 3; n=112; evaluation: not stated. Reported fields: -; -; -

A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006)

Phase 3; n=150; evaluation: Positive. Reported fields: Efficacy Patient Level: P-Value = <0.001; Efficacy Patient Level = 33.0 % (95%CI, 24.3 - 42.7)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Pafolacianine addresses Lung Cancer, Contrast agents, Ovarian Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug, Fluorescent dyes—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 0 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: FOLR1 x FOLR2 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
No matched asset transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO